Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study
Cancer Control · 2025
DOI: 10.1177/10732748251323730 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Control, 2025. Verfasst von Aneta Maria Borkowska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Hauptthemen laut MEDLINE: Chordoma, Sacrum, Spinal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chordoma is a rare and aggressive primary bone sarcoma. En-block resection remains the primary treatment, but some patients are unable to undergo it due to the location and potential complications. Currently, there is no direct comparison of the effects of radiotherapy (RTH) and surgical treatment. However, retrospective analyses indicate the potential benefits of using RTH.
Methods
A retrospective analysis was conducted on 48 patients with sacral chordoma who were treated with surgery and/or radiotherapy between 2001-2020. Among those, 22 were initially treated with surgery, 19 with definitive radiotherapy, and 7 received combined treatment. The outcomes of the treatment of recurrence in 16 patients were considered. The resection margins were defined according to R classification, and the Kaplan-Meier method was employed to calculate disease-free survival (DFS) and overall survival (OS).
Results
The median (mOS) for the entire cohort was 80.6 months (95% CI: 62.3-NA), and the median (mDFS) was 40.4 months (95% CI: 35-69.5). Patients who underwent radical surgery of the primary tumor did not achieve the mOS (mean 68), while patients treated only with RTH for the primary tumor achieved an mOS of 62.3 months (95% CI: 52.1-NA). This resulted in a significant advantage of surgery over RTH in terms of OS ( P = 0.01). This was not observed for DFS. The 3-year DFS rates were 65% in the surgical treatment group and 53.3% in the RTH group. The 3-year OS rates were 96% in the surgery group and 88.9% in the RTH group. In the treatment of recurrence, there were no statistically significant differences between RTH and surgery, for OS ( P = 0.76).
Conclusions
Radical surgery remains the optimal treatment for sacral chordoma. For patients who are not candidates for surgical intervention, RTH offers excellent long-term outcomes. The treatment of recurrence remains a significant challenge. Comparing modern RTH techniques and surgical procedures could provide further insights.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
- Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
ORCID-Profile: Paulina Chmiel, Tomasz Skóra
Zitieren
APA
Borkowska, A. M., Pieńkowski, A., Chmiel, P., Skóra, T., Michalik, R., Rutkowski, P., & Spałek, M. J. (2025). Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study. Cancer Control. https://doi.org/10.1177/10732748251323730
Vancouver
Borkowska AM, Pieńkowski A, Chmiel P, Skóra T, Michalik R, Rutkowski P, et al. Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study. Cancer Control. 2025. doi:10.1177/10732748251323730
BibTeX
@article{Borkowska2025,
author = {Borkowska, Aneta Maria and Pieńkowski, Andrzej and Chmiel, Paulina and Skóra, Tomasz and Michalik, Radosław and Rutkowski, Piotr and Spałek, Mateusz Jacek},
title = {Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study},
journal = {Cancer Control},
year = {2025},
doi = {10.1177/10732748251323730}
}
EUVIMED